These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19046202)

  • 41. Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes.
    Yuan G; Jia J; Zhang C; Yu S; Dong S; Ye J; Zhu T; Tang B; Qian W; Wang D; Yang L; Zhou L; Mao C
    Endocr J; 2014; 61(5):513-21. PubMed ID: 24621778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.
    Andreou ER; Ledger S
    Can J Clin Pharmacol; 2003; 10(4):172-4. PubMed ID: 14712320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simvastatin-fluconazole causing rhabdomyolysis.
    Shaukat A; Benekli M; Vladutiu GD; Slack JL; Wetzler M; Baer MR
    Ann Pharmacother; 2003; 37(7-8):1032-5. PubMed ID: 12841814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis.
    Kanathur N; Mathai MG; Byrd RP; Fields CL; Roy TM
    Tenn Med; 2001 Sep; 94(9):339-41. PubMed ID: 11550401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report.
    Godinho R; Bugnon S; Gracin T; Tataw J
    BMC Nephrol; 2019 Feb; 20(1):69. PubMed ID: 30808332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simvastatin-induced rhabdomyolysis and acute renal injury.
    Waness A; Bahlas S; Al Shohaib S
    Blood Purif; 2008; 26(4):394-8. PubMed ID: 18594138
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes.
    Florentin M; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 Jul; 9(10):1705-20. PubMed ID: 18570604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
    Pendergrass M; Fenton C; Haffner SM; Chen W
    Diabetes Obes Metab; 2012 Jul; 14(7):596-600. PubMed ID: 22268550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sitagliptin and Simvastatin Interaction Causing Rhabdomyolysis and AKI.
    Patel C; Thompson C; Copley-Harris M; Hattab Y
    Case Rep Med; 2019; 2019():2601537. PubMed ID: 30936920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
    Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Rhabdomyolysis as a side effect of simvastatin treatment].
    Iskra B; Zivko M; Kes P
    Acta Med Croatica; 2005; 59(4):325-8. PubMed ID: 16334740
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy.
    Marais GE; Larson KK
    Ann Intern Med; 1990 Feb; 112(3):228-30. PubMed ID: 2297197
    [No Abstract]   [Full Text] [Related]  

  • 53. Severe rhabdomyolysis associated with concurrent use of simvastatin and sirolimus after cisplatin-based chemotherapy in a kidney transplant recipient.
    Hong YA; Kim HD; Jo K; Park YK; Lee J; Sun IO; Chung BH; Park CW; Yang CW; Choi BS
    Exp Clin Transplant; 2014 Apr; 12(2):152-5. PubMed ID: 23734754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
    Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
    Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rhabdomyolysis with acute renal failure triggered by the seasonal flu vaccination in a patient taking simvastatin.
    Shah SV; Reddy K
    BMJ Case Rep; 2010 Oct; 2010():. PubMed ID: 22778082
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DPP-IV inhibitor-associated arthralgias.
    Chaicha-Brom T; Yasmeen T
    Endocr Pract; 2013; 19(2):377. PubMed ID: 23598537
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
    Skalli S; Wion-Barbot N; Baudrant M; Lablanche S; Benhamou PY; Halimi S
    Diabet Med; 2010 Apr; 27(4):486-7. PubMed ID: 20536525
    [No Abstract]   [Full Text] [Related]  

  • 59. [Maximal initial dose of simvastatin causing acute renal failure through rhabdomyolysis: risk factors, pathomechanism and therapy related to a case].
    Deme D; Al-Hadad A; Varga T; Szántó E; Sándor K; Rakonczai E
    Orv Hetil; 2009 Feb; 150(6):265-9. PubMed ID: 19179259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.
    Yokota K; Igaki N
    Intern Med; 2012; 51(15):2041-4. PubMed ID: 22864134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.